Akero Therapeutics's total assets for Q1 2025 were $1.16B, an increase of 39.95% from the previous quarter. AKRO total liabilities were $72.00M for the fiscal quarter, a -4.98% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.